Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL162359 | 0.93 | ALDH1A1 (0.39) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL716817 | 0.86 | ALDH1A1 (0.36) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6950111 | 0.86 | TSHR (0.39) | POLBKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL12140577 | 0.86 | ALDH1A1 (0.36) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL20512092 | 0.85 | POLB (0.38) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6777001 | 0.85 | TSHR (0.36) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL32670608 | 0.84 | MAPT (0.41) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17540555 | 0.83 | CYP4F2 (0.44) | ALDH1A1KDM4ELMNA | |
| SCHEMBL19209048 | 0.82 | POLB (0.40) | POLBKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL20512040 | 0.82 | POLB (0.38) | POLBKMT2AALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242973-B2 | Chromane compounds | COMENTIS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150225386-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150225386-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. | 2015-08-13 | — | — | US | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975415-B2 | Chromane compounds | COMENTIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179695-A1 | CHROMANE COMPOUNDS | COMENTIS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| WO-2013181202-A2 | CHROMANE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2013-12-05 | — | — | WO | disclosed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179695-A1 | CHROMANE COMPOUNDS | BACE1, BACE2, APP | POLB 1948/4885KMT2A 3884/4885ALDH1A1 4139/4885 |
| US-20150225386-A1 | CHROMANE COMPOUNDS | BACE1, BACE2, APP | POLB 2090/4885KMT2A 3037/4885ALDH1A1 3038/4885 |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | POLB 2855/4885KMT2A 3967/4885ALDH1A1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.